The remaining 65 patients completed the 48-week treatment and 24-week posttreatment follow up. Some characteristics
of the patients at retreatment were different from those at initial treatment (Table 1), including age (around 3 years older), body weight (body mass index [BMI], 0.2 kg/m2 increase), and aspartate aminotransferases-to-platelet ratio index (APRI, 1.3 increase). At retreatment, the majority of the patients were older than 50 years of age (77%) and male predominated (56%), 47% of the patients had a BMI of 25 kg/m2 or greater, and 60% had a serum ALT level greater than two times the ULN (Table 1). As for the IL28B genotype (rs8099917), TT genotype was predominant (TT learn more vs GT vs GG = 72% vs 28% vs 0%) (Table S1). Clinical and virologic parameters before retreatment were not statistically significant between TT and GT genotype. Rate of RVR, EOT-VR, and SVR was 37%, 73%, and 52%, respectively. Relapse rate was 29% (Fig. 2). At week 12 of treatment, 13% patients did not achieve EVR, 13% achieved pEVR, and 36% attained cEVR. According to IL28B genotype, patients with TT genotype had higher rates
of RVR (50% vs 5%, P = 0.0002), EOT-VR (85% vs 43%, P = 0.0001), and SVR (67% vs 14%, P = 0.0001) in comparison with GT genotype (Fig. 2). Those with GT genotype cleared serum HCV RNA slower (higher proportion of pEVR or cEVR) than TT genotype. GT genotype had a higher relapse rate than TT genotype (67% vs 22%, P = 0.006). Achieving a RVR ensured a higher EOT-VR rate (96% vs 59% for RVR and non-RVR, respectively; P = 0.0003), higher SVR rate (86% vs 32% for RVR and non-RVR, respectively; P < 0.0001), and lower relapse rate (11% vs Pexidartinib price 46% for RVR and non-RVR, respectively; P = 0.0034) (Fig. 3). The IL28B TT genotype increased the chance of attaining SVR (67% vs 14% for TT and GT, respectively; P < 0.0001) (Fig. 4). However, in those who achieved RVR, SVR rates were independent of IL28B SNP genotype (85% vs 100% for TT and GT, respectively). In contrast, in patients who did not achieve RVR, the effect of IL28B genotype was significant; SVR rates were significantly higher
in patients with the TT genotype (48% for TT vs 10% for GT; P = 0.0048); the rate of relapse tended to be lower Interleukin-2 receptor (35% for TT vs 75% for GT; P = 0.0581). Viral reduction in week 12 during treatment also influenced SVR rate in patients who did not achieve a RVR (10% for pEVR[+] vs 52% for cEVR[+]; P = 0.015). Seventy-one percent of patients whose HCV RNA was undetectable at the end of treatment (i.e. EOT-VR) attained SVR; the rate was significantly higher in TT genotype (78% for TT vs 33% for GT; P = 0.006). Female sex, less BMI, lower fasting glucose level, higher serum albumin, and lower baseline HCV RNA level were associated with RVR. TT genotype was the only independent predictive factor of RVR (OR = 20; 95% CI = 2.5–159.8; P = 0.005). TT genotype (OR = 12; 95% CI = 3.12–46.14; P < 0.001) and RVR (OR = 12.